Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing
Executive Summary
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
INTERVIEW: DPx's Jim Mullen delivers the $2.6bn message
The recent merger of Patheon and DPP makes the company one of the largest outsourcing players in the market. CEO Jim Mullen explains why the company now has to live up to the hype.